Is ONCOLYTICS BIOTECH INC (ONCY) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.9% / 30% | 14.0% / 30% | 0.1% / 30% | N/A | ✓ HALAL |
| DJIM | 0.9% / 33% | 14.0% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| MSCI | 5.3% / 33% | 79.0% / 33% | 0.3% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.9% / 33% | 14.0% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| FTSE | 5.3% / 33% | 79.0% / 33% | 0.3% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -769.1% | |
| Return on Assets (ROA) | -111.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$27M |
| Free Cash Flow | -$27M |
| Total Debt | $1M |
| Debt-to-Equity | 726.1 |
| Current Ratio | 1.8 |
| Total Assets | $20M |
Price & Trading
| Last Close | $0.90 |
| 50-Day MA | $1.00 |
| 200-Day MA | $1.04 |
| Avg Volume | 1.3M |
| Beta | 0.9 |
|
52-Week Range
$0.33
| |
About ONCOLYTICS BIOTECH INC (ONCY)
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ONCOLYTICS BIOTECH INC (ONCY) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ONCOLYTICS BIOTECH INC is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ONCOLYTICS BIOTECH INC's debt ratio?
ONCOLYTICS BIOTECH INC's debt ratio is 0.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.3%.
What are ONCOLYTICS BIOTECH INC's key financial metrics?
ONCOLYTICS BIOTECH INC has a market capitalization of $90M. Return on equity stands at -769.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.